Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2021-05-07. The firm is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. The company is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
Follow-Up Questions
Who is the CEO of Tourmaline Bio Inc?
Dr. Sandeep Kulkarni is the Chief Executive Officer of Tourmaline Bio Inc, joining the firm since 2023.
What is the price performance of TRML stock?
The current price of TRML is $47.98, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Tourmaline Bio Inc?
Tourmaline Bio Inc belongs to Biotechnology industry and the sector is Health Care
What is Tourmaline Bio Inc market cap?
Tourmaline Bio Inc's current market cap is $1.2B
Is Tourmaline Bio Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Tourmaline Bio Inc, including 6 strong buy, 10 buy, 1 hold, 0 sell, and 6 strong sell
